Suvretta Capital Management LLC boosted its holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 31.1% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 6,783,091 shares of the company's stock after buying an additional 1,607,268 shares during the period. EyePoint Pharmaceuticals accounts for approximately 1.7% of Suvretta Capital Management LLC's holdings, making the stock its 15th biggest position. Suvretta Capital Management LLC owned about 9.94% of EyePoint Pharmaceuticals worth $50,534,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also bought and sold shares of the company. Barclays PLC boosted its stake in shares of EyePoint Pharmaceuticals by 410.4% in the third quarter. Barclays PLC now owns 245,045 shares of the company's stock worth $1,959,000 after acquiring an additional 197,033 shares during the period. JPMorgan Chase & Co. lifted its holdings in EyePoint Pharmaceuticals by 1,171.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 371,758 shares of the company's stock worth $2,970,000 after purchasing an additional 342,516 shares in the last quarter. abrdn plc bought a new position in EyePoint Pharmaceuticals in the 4th quarter worth approximately $1,719,000. Raymond James Financial Inc. bought a new position in EyePoint Pharmaceuticals in the 4th quarter worth approximately $76,000. Finally, Rhumbline Advisers grew its holdings in EyePoint Pharmaceuticals by 16.1% during the 4th quarter. Rhumbline Advisers now owns 89,560 shares of the company's stock valued at $667,000 after buying an additional 12,443 shares in the last quarter. 99.41% of the stock is owned by institutional investors.
EyePoint Pharmaceuticals Trading Up 1.8%
Shares of NASDAQ:EYPT traded up $0.11 during trading on Tuesday, reaching $6.21. The company's stock had a trading volume of 695,713 shares, compared to its average volume of 816,881. The stock has a market capitalization of $427.32 million, a PE ratio of -3.11 and a beta of 1.58. EyePoint Pharmaceuticals, Inc. has a 12 month low of $3.91 and a 12 month high of $13.99. The firm's 50 day simple moving average is $5.87 and its two-hundred day simple moving average is $7.25.
EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.65) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.65). The business had revenue of $24.50 million during the quarter, compared to analyst estimates of $8.84 million. EyePoint Pharmaceuticals had a negative return on equity of 43.01% and a negative net margin of 226.57%. Research analysts anticipate that EyePoint Pharmaceuticals, Inc. will post -2.13 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
EYPT has been the topic of several research analyst reports. Mizuho lowered their target price on shares of EyePoint Pharmaceuticals from $30.00 to $26.00 and set an "outperform" rating on the stock in a report on Friday. HC Wainwright reiterated a "buy" rating and issued a $22.00 price target on shares of EyePoint Pharmaceuticals in a research note on Thursday, March 6th. Chardan Capital cut their price objective on EyePoint Pharmaceuticals from $33.00 to $27.00 and set a "buy" rating for the company in a research report on Thursday, May 8th. Finally, StockNews.com upgraded EyePoint Pharmaceuticals to a "sell" rating in a research report on Friday, March 14th. One research analyst has rated the stock with a sell rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $25.38.
Get Our Latest Stock Report on EYPT
About EyePoint Pharmaceuticals
(
Free Report)
EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.
Recommended Stories
Before you consider EyePoint Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and EyePoint Pharmaceuticals wasn't on the list.
While EyePoint Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
